News 20.10.2019 Schlieren, Switzerland – October 16, 2019 – AL-S Pharma AG, a biotech company jointly founded and financed by Neurimmune and TVM Capital Life Science, announced today enrollment of the first patient in a multicenter Phase 1 clinical trial to evaluate AP-101 in patients with amyotrophic lateral sclerosis (ALS). AP-101 is...
News 20.10.2019 DUBLIN, IRELAND – OCTOBER 11, 2019 – Allergan plc, (NYSE: AGN), a leading global pharmaceutical company with a more than 70-year heritage in ophthalmology and Molecular Partners (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies, today announced two-year data from the CEDAR...
News 03.10.2019 Zurich-Schlieren, October 3, 2019. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of drugs known as DARPin® therapies, today announced that the first patient has been enrolled and dosed in a Phase 1 first-in-human study of MP0310 as a single agent in patients...
News 24.09.2019 Schlieren (Zurich), Switzerland, September 24, 2019 – Kuros Biosciences, a leader in next generation bone graft technologies, today announces the full commercial launch of MagnetOs™ and the company’s first attendance as an exhibitor at NASS, the world’s largest spine meeting and exhibition. During the meeting, the commercial team will be...
News 09.09.2019 DUBLIN, IRELAND – SEPT 9, 2019 – Allergan plc (NYSE: AGN), a leading global pharmaceutical company with a heritage of more than 70 years in eye care, and Molecular Partners (SIX: MOLN), a clinical-stage biotechnology company developing a new class of drugs known as DARPin® platform, today announced that the U.S. Food and...